Triple Negative Breast Cancer (TNBC)
~Introduction
Breast cancer is the most common cancer among women worldwide and a leading cause of cancer-related mortality. It is not a single disease but a group of tumors with different biological behaviors, responses to treatment, and prognoses. One of the most aggressive and challenging subtypes is Triple Negative Breast Cancer (TNBC).
Triple Negative Breast Cancer accounts for approximately 10–15% of all breast cancers. It is characterized by the absence of three receptors that commonly guide breast cancer treatment: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Because these receptors are absent, hormonal therapy and HER2-targeted therapy are ineffective, making TNBC difficult to treat.
TNBC is associated with rapid growth, early metastasis, high recurrence rates, and a generally poor prognosis compared to other breast cancer subtypes. However, recent advances in chemotherapy, immunotherapy, and targeted treatments have improved outcomes for many patients.
~Definition of Triple Negative Breast Cancer
Triple Negative Breast Cancer is defined as a breast carcinoma that:
Lacks estrogen receptors (ER-negative)
Lacks progesterone receptors (PR-negative)
Does not overexpress HER2 protein (HER2-negative)
Diagnosis is confirmed by immunohistochemistry (IHC) and sometimes fluorescence in situ hybridization (FISH) testing.
~Epidemiology
TNBC represents 10–15% of all breast cancers
More common in:
Women younger than 50 years
Premenopausal women
African and Hispanic women
Women with BRCA1 gene mutations
Occurs in both genders but is extremely rare in men
~Risk Factors
Genetic Factors
BRCA1 mutation is strongly associated with TNBC
Other genetic mutations: TP53, PALB2
Demographic Factors
Younger age at diagnosis
Certain ethnic populations
Reproductive and Lifestyle Factors
Early menarche
Obesity
Lack of breastfeeding
Smoking and alcohol use
~Pathogenesis and Molecular Features
TNBC is biologically heterogeneous. Most TNBC tumors are basal-like cancers that resemble the basal cells of normal breast ducts.
Key Molecular Characteristics
High expression of Ki-67 (high proliferation index)
Frequent TP53 mutations
Genomic instability
Defects in DNA repair pathways
Molecular Subtypes of TNBC
Basal-like 1
Basal-like 2
Immunomodulatory
Mesenchymal
Luminal androgen receptor (LAR)
These subtypes help guide emerging targeted therapies.
~Histopathology
Common Histological Types
Invasive ductal carcinoma (most common)
Medullary carcinoma
Metaplastic carcinoma
Microscopic Features
High nuclear grade
Marked pleomorphism
High mitotic activity
Areas of necrosis
Prominent lymphocytic infiltration
~Clinical Presentation
Patients with TNBC usually present with:
A rapidly growing breast lump
Breast pain or discomfort
Skin changes (dimpling, redness)
Nipple retraction or discharge (less common)
Enlarged axillary lymph nodes
TNBC tumors often grow faster and are larger at the time of diagnosis.
~Diagnosis
Clinical Examination
Breast and lymph node assessment
Imaging Studies
Mammography
Ultrasound
MRI (useful in young women)
Tissue Diagnosis
Core needle biopsy
Fine needle aspiration (FNA)
Immunohistochemistry (IHC)
ER: Negative
PR: Negative
HER2: Negative
Genetic Testing
Recommended for patients with TNBC diagnosed under 60 years
BRCA mutation testing
~Staging
TNBC is staged using the TNM system:
T – Tumor size
N – Lymph node involvement
M – Distant metastasis
Common sites of metastasis:
Lungs
Liver
Brain
Bone (less frequent compared to hormone-positive cancers)
~Treatment of Triple Negative Breast Cancer
Because TNBC lacks hormonal and HER2 receptors, treatment relies heavily on systemic chemotherapy, along with surgery and radiotherapy.
Surgical Management
Breast-conserving surgery (lumpectomy) for early disease
Modified radical mastectomy for large tumors
Sentinel lymph node biopsy or axillary dissection
Chemotherapy
Chemotherapy is the mainstay of TNBC treatment.
Neoadjuvant Chemotherapy
Given before surgery
Helps shrink tumor
Allows breast conservation
Pathological complete response (pCR) predicts better survival
Common drugs:
Anthracyclines (doxorubicin)
Taxanes (paclitaxel)
Platinum agents (carboplatin)
Adjuvant Chemotherapy
Given after surgery
Reduces recurrence risk
Radiotherapy
Used after breast-conserving surgery
Used after mastectomy in high-risk patients
Reduces local recurrence
~Targeted and Novel Therapies
PARP Inhibitors
Effective in BRCA-mutated TNBC
Examples: Olaparib, Talazoparib
Exploit defective DNA repair mechanisms
Immunotherapy
TNBC is more immunogenic than other breast cancers.
Immune checkpoint inhibitors:
Pembrolizumab
Atezolizumab
Used in combination with chemotherapy
Improves survival in PD-L1 positive tumors
Androgen Receptor Targeting
For Luminal Androgen Receptor subtype
Anti-androgen therapies under study
~Prognosis
TNBC generally has a worse prognosis than other breast cancer types.
Key Prognostic Factors
Tumor size
Lymph node involvement
Response to chemotherapy
Presence of BRCA mutation
Recurrence Pattern
Highest risk within first 3–5 years
Lower late recurrence compared to hormone-positive cancers
Survival Rates
Early-stage TNBC: Good outcomes with treatment
Advanced/metastatic TNBC: Poor prognosis
~Complications
Early metastasis
Chemotherapy-related toxicity
Psychological distress
Body image issues after surgery
~Prevention and Screening
Genetic counseling for high-risk individuals
Regular breast screening
Lifestyle modification
Prophylactic surgery in BRCA mutation carriers
~Psychosocial Aspects
TNBC diagnosis can be emotionally distressing due to its aggressive nature.
Anxiety and depression are common
Importance of psychological counseling
Support groups and survivorship programs
~Recent Advances and Research
Development of antibody-drug conjugates
Personalized medicine based on molecular profiling
Combination immunotherapy strategies
Liquid biopsy for monitoring disease
~Conclusion
Triple Negative Breast Cancer is an aggressive and complex subtype of breast cancer characterized by the absence of estrogen, progesterone, and HER2 receptors. It affects younger women, shows rapid progression, and has limited targeted treatment options compared to other breast cancer types.
Despite these challenges, advances in chemotherapy, immunotherapy, PARP inhibitors, and molecular research have significantly improved outcomes. Early diagnosis, aggressive multimodal treatment, genetic testing, and supportive care play a crucial role in improving survival and quality of life.
Ongoing research and clinical trials continue to offer hope for more effective and personalized therapies for patients with Triple Negative Breast Cancer.
No comments:
Post a Comment